Men less likely to survive early breast cancer

Key points
- While breast cancer is far more common in women than in men, men may be more likely to die from early-stage breast tumors, a new study suggests.
- Male breast cancer is rare, accounting for less than 1 percent of all breast cancers.
- The rarity of breast cancer in men has prevented clinical trials, and treatment is based on what's known about female breast cancer.
- But the new findings, published in the journal Cancer, suggest that there may be biological differences in male and female breast cancers that affect survival.
While breast cancer is far more common in women than in men, men may be more likely to die from early-stage breast tumors, a new study suggests.
Male breast cancer is rare, accounting for less than 1 percent of all breast cancers. But unlike the case with breast cancer in women, there have been no improvements in survival the past 30 years in men with this disease.
The rarity of breast cancer in men has prevented clinical trials, and treatment is based on what's known about female breast cancer.
But the new findings, published in the journal Cancer, suggest that there may be biological differences in male and female breast cancers that affect survival. Specifically, men with relatively small tumors or tumors that had not yet spread to the lymph nodes had a shorter survival time than their female counterparts.
Among men whose breast cancer had not spread to the lymph nodes, the typical survival time was 6 years, compared with nearly 15 years among women.
The difference suggests a need for better understanding of male breast cancer, and improved treatments, according to Dr. Zeina A. Nahleh and her colleagues at the University of Cincinnati.
The researchers based their findings on a large cancer registry maintained by Veterans' Affairs. They reviewed the records of 612 men treated for breast cancer and compared them with 2,413 women treated for the disease.
While Nahleh's team found no difference in survival times of men and women with more-advanced breast cancer, they did find one among patients with earlier-stage tumors.
When it came to treatment, men had lower rates of both chemotherapy and radiation than women did, but they were as likely as women to receive hormone therapy.
Hormonal therapies for breast cancer, such as the drug tamoxifen, block the ability of estrogen to fuel tumor growth. As in women, men's breast tumor cells often have receptors for estrogen, which means hormone therapy can be helpful.
However, Nahleh and her colleagues write, it's possible that men's breast tumors do not respond well to standard therapy with tamoxifen.
"A better understanding of this disease is needed," they conclude, "so that new opportunities for therapeutic intervention may be developed."
SOURCE: Cancer, April 15, 2007.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsWomen with severe, chronic health issues are screened for breast cancer less often
Women with severe disabilities and multiple chronic conditions are screened for breast cancer less often than women with no disabilities or no chronic conditions, a new study has found. They are also screened less often…
24 August 2014
NewsYale researchers identify targets for immunotherapy in early-stage breast cancer
Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the…
19 July 2014
NewsFaster genetic testing method will likely transform care for patients with breast cancer
Faster and cheaper DNA sequencing techniques will likely improve care for patients with breast cancer but also create challenges for clinicians as they counsel patients on their treatment options. Those are among the…


